senate Bill S5338A

2015-2016 Legislative Session

Enacts the pharmaceutical cost transparency act of 2016

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Senate Committee Health Committee


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

Your Voice

do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

view actions (4)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Jan 20, 2016 print number 5338a
Jan 20, 2016 amend (t) and recommit to health
Jan 06, 2016 referred to health
May 13, 2015 referred to health

Co-Sponsors

S5338 (ACTIVE) - Details

Current Committee:
Senate Health
Law Section:
Public Health Law
Laws Affected:
Add §278-a, Pub Health L
Versions Introduced in 2017-2018 Legislative Session:
S4986

S5338 (ACTIVE) - Summary

Enacts the pharmaceutical cost transparency act requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.

S5338 (ACTIVE) - Sponsor Memo

S5338 (ACTIVE) - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  5338

                       2015-2016 Regular Sessions

                            I N  S E N A T E

                              May 13, 2015
                               ___________

Introduced  by  Sen.  DIAZ  --  read twice and ordered printed, and when
  printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to  establishing  the
  pharmaceutical cost transparency act of 2015

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. This act shall be cited and may be known as the "pharmaceu-
tical cost transparency act of 2015".
  S 2. The public health law is amended by adding a new section 278-a to
read as follows:
  S 278-A. PRESCRIPTION DRUG COST TRANSPARENCY. 1.  LEGISLATIVE  INTENT.
A.  IT IS THE INTENT OF THE LEGISLATURE TO MAKE INFORMATION AVAILABLE TO
THE PUBLIC ABOUT THE COST OF ULTRA-HIGH-PRICED PHARMACEUTICALS, IN ORDER
TO MAKE PHARMACEUTICAL PRICING AS TRANSPARENT AS THE  PRICING  IN  OTHER
SECTORS OF THE HEALTH CARE INDUSTRY.
  B. THE LEGISLATURE FINDS THAT THERE SHOULD BE ANNUAL COST REPORTING ON
THE  MOST  EXPENSIVE DRUGS THAT WOULD BE OF USE TO POLICYMAKERS, GOVERN-
MENT AGENCIES, AND  OTHERS  TO  UNDERSTAND  COSTS  FOR  THESE  IMPORTANT
PRODUCTS.
  2.  EACH  MANUFACTURER  OF  A PRESCRIPTION DRUG, MADE AVAILABLE IN NEW
YORK, THAT HAS A WHOLESALE ACQUISITION  COST  OF  TEN  THOUSAND  DOLLARS
($10,000)  OR  MORE  ANNUALLY  OR  PER COURSE OF TREATMENT, SHALL FILE A
REPORT PURSUANT TO THIS SECTION ON THE COSTS FOR EACH QUALIFYING DRUG.
  3. THE REPORT REQUIRED PURSUANT TO SUBDIVISION  TWO  OF  THIS  SECTION
SHALL INCLUDE ALL OF THE FOLLOWING FOR EACH DRUG:
  A.  THE  TOTAL  COSTS FOR THE PRODUCTION OF THE DRUG, INCLUDING ALL OF
THE FOLLOWING:
  (I) THE TOTAL RESEARCH AND DEVELOPMENT COSTS PAID BY THE MANUFACTURER,
AND SEPARATELY, THE TOTAL RESEARCH AND DEVELOPMENT  COSTS  PAID  BY  ANY
PREDECESSOR IN THE DEVELOPMENT OF THE DRUG.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD11025-02-5

Co-Sponsors

S5338A (ACTIVE) - Details

Current Committee:
Senate Health
Law Section:
Public Health Law
Laws Affected:
Add §278-a, Pub Health L
Versions Introduced in 2017-2018 Legislative Session:
S4986

S5338A (ACTIVE) - Summary

Enacts the pharmaceutical cost transparency act requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.

S5338A (ACTIVE) - Sponsor Memo

S5338A (ACTIVE) - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 5338--A

                       2015-2016 Regular Sessions

                            I N  S E N A T E

                              May 13, 2015
                               ___________

Introduced by Sens. DIAZ, PERKINS -- read twice and ordered printed, and
  when printed to be committed to the Committee on Health -- recommitted
  to the Committee on Health in accordance with Senate Rule 6, sec. 8 --
  committee  discharged,  bill amended, ordered reprinted as amended and
  recommitted to said committee

AN ACT to amend the public health law, in relation to  establishing  the
  pharmaceutical cost transparency act of 2016

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. This act shall be cited and may be known as the "pharmaceu-
tical cost transparency act of 2016".
  S 2. The public health law is amended by adding a new section 278-a to
read as follows:
  S 278-A. PRESCRIPTION DRUG COST TRANSPARENCY. 1.  LEGISLATIVE  INTENT.
A.  IT IS THE INTENT OF THE LEGISLATURE TO MAKE INFORMATION AVAILABLE TO
THE PUBLIC ABOUT THE COST OF ULTRA-HIGH-PRICED PHARMACEUTICALS, IN ORDER
TO MAKE PHARMACEUTICAL PRICING AS TRANSPARENT AS THE  PRICING  IN  OTHER
SECTORS OF THE HEALTH CARE INDUSTRY.
  B. THE LEGISLATURE FINDS THAT THERE SHOULD BE ANNUAL COST REPORTING ON
THE  MOST  EXPENSIVE DRUGS THAT WOULD BE OF USE TO POLICYMAKERS, GOVERN-
MENT AGENCIES, AND  OTHERS  TO  UNDERSTAND  COSTS  FOR  THESE  IMPORTANT
PRODUCTS.
  2.  EACH  MANUFACTURER  OF  A PRESCRIPTION DRUG, MADE AVAILABLE IN NEW
YORK, THAT HAS A WHOLESALE ACQUISITION  COST  OF  TEN  THOUSAND  DOLLARS
($10,000)  OR  MORE  ANNUALLY  OR  PER COURSE OF TREATMENT, SHALL FILE A
REPORT PURSUANT TO THIS SECTION ON THE COSTS FOR EACH QUALIFYING DRUG.
  3. THE REPORT REQUIRED PURSUANT TO SUBDIVISION  TWO  OF  THIS  SECTION
SHALL INCLUDE ALL OF THE FOLLOWING FOR EACH DRUG:
  A.  THE  TOTAL  COSTS FOR THE PRODUCTION OF THE DRUG, INCLUDING ALL OF
THE FOLLOWING:

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD11025-03-6

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.